Insulin treatment and weight gain in type 2 diabetes: Is our knowledge complete?

Current Nutrition and Food Science

Volumn 2, Issue 1, 2006, Pages 51-58

  Ryan, Miriam ^a,b   Livingstone, M Barbara E ^b   Ritz, Patrick ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Diabetes; Energy intake; Insulin; Weight gain

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

APPETITE; BODY WEIGHT DISORDER; CALORIC INTAKE; DIET THERAPY; DISEASE ASSOCIATION; DISEASE CONTROL; ENERGY BALANCE; ENERGY EXPENDITURE; EXERCISE; FEEDING BEHAVIOR; FOOD INTAKE; GLUCOSURIA; HUMAN; INSULIN RESISTANCE; MEDICAL LITERATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; REVIEW; WEIGHT GAIN;

EID: 33745830145     PISSN: 15734013     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340106775471958     Document Type: Review

References (97)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Diabetes Care 2004;27:1047-53.
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025 prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31
3. Hotu S, Carter B, Watson P, Cutfield W, Cundy T. Increasing prevalence of type 2 diabetes in adolescents. J Paediatr Child Health 2004; 40: 201-4.
4. Knowler WC, Pettitt DJ, Saad HP, Charles MA, Nelson RG, Howard BV, Bogardus C, Bennett PH. Obesity in the Pima Indians: its magnitude and relationship with diabetes. Am J Clin Nutr 1991; 53: 1543-51S.
5. Ruderman NB, Williamson JR, Brownlee M. Glucose and diabetic vascular disease. FASEB J 1992; 6:2905-14.
6. UK Prospective Diabetes Study Group. Hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes (UKPDS 59). Diabetes Care 2002; 25: 894-9.
7. Di Carli MF, Janisse J, Grunberger G, Ager J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 2003; 16: 1387-93.
8. Eschwege E, Richard JL, Thibult N, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris Prospective Study, ten years later. Horm Metab Res 1985; 15: 41-6.
9. Lawrence J, Robinson A. Screening for diabetes in general practice. Prev Cardiol 2003; 6: 78-84.
10. Cowie CC, Harris MI. In: Bethescla MD Ed, Diabetes in America: Physical and metabolic characteristics of persons with diabetes. Rockville, NIH Press 1995; 117-133.
11. Gould AJ, Williams DE, Byrne CD, Hales CN, Wareham NJ. Prospective cohort study of the relationship of markers of insulin resistance and secretion with weight gain and changes in regional adiposity. Int J Obes Relat Metab Disord 1999; 23: 1256-61.
12. Ross R, Aru J, Freeman J, Hudson R, Janssen I. Abdominal adiposity and insulin resistance in obese men. Am J Physiol Endocrinol Metab 2002; 282: E657-63.
13. Woods SC, Seeley RJ. Insulin as an adiposity signal. Int J Obes Relat Metab Disord 2001; 25: 535-8.
14. Polonsky KS, Given BD, Van Canter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988; 81: 442-8.
15. Bagdade JD, Bierman EL, Porte D Jr. The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects. J Clin Invest 1967; 46: 1549-57.
16. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-52.
17. Pavo I, Jermendy G, Varkonyi TT, Kerenyi Z, Gyimesi A, Shoustov S, Shestakova. M, Herz M, Johns D, Schluchter BJ, Festa A, Tan MH. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88:1637-45.
18. Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of Troglitazone in insulin-treated patients with type 2 diabetes mellitus. N Eng J Med 1998; 338: 861-6.
19. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 1998; 12: 854-65.
20. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type 2 non-insulin-dependent diabetes. Obes Res 1998; 6: 47-53.
21. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group. Arcarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002; 15: 2072-7.
22. Ricordeau P, Weil A, Vallier N, Bourrel R, Finder P, Allemand H. [The epidemiology of diabetes in mainland France] (French). Diabet Metab 2000; 26: 11-24.
23. Lundman B, Engstrom L. Diabetes and it's complications in a Swedish county. Diabetes Res Clin Pract 1998; 39: 157-64.
24. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004; 27: 1028-32.
25. Sallé A, Guilloteau G, Ryan M, Bouhanick B, Ritz P. Effect of insulin treatment on body composition of type 2 diabetics. Diabetic Medicine 2004; 21: 1298-1303.
26. Makimattila S, Nikkila V, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type 2 diabetes mellitus. Diabetologia 1999; 42: 406-12.
27. UK Prospective Diabetes Study Group. Overview of six year's of type 2 diabetes- a progressive disease (UKPDS 16). Diabetes 1995; 44: 1249-58.
28. Yki-Jarvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajala S, Ryysy L, Salo S, Seppala P, Tulokas T, Viikari J, Karjalainen J, Taskinen MR. Comparison of Insulin regimens in Patients with Non-Insulin-Dependent Diabetes Mellitus. N Eng J Med 1992; 327: 1426-33.
29. Olsson PO, Lindstrom T. Combination-therapy with bedtime NPH insulin and sulphonlyureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes. Diabetes Metab 2002; 28: 272-7.
30. Sinha A, Formica C, Tsalamandris C, Panagiotopoulos S, Henrich E, DeLuise M, Seeman E, Jerums G. Effects of insulin on body composition in patients with insulin-dependent and non-insulin-dependent diabetes. Diabet Med 1996; 13: 40-6.
31. Chow CC, Tsang LWW, Sorensen JP, Cockram CS. Comparison of Insulin with or without Continuation of Oral Hypoglycemic Agents in the Treatment of Secondary Failure in NIDDM Patients. Diabetes Care 1995; 18: 307-14.
32. Groop L, Widen E, Franssila-Kallunki A, Ekstrand A, Saloranta C, Schalin C, Eriksson J. Different effects of insulin and oral antidabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989; 32: 599-605.
33. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type 2 diabetes: Metabolic effects during a 6-mo outpatient trial. Diabetes Care 1993; 16: 21-31.
34. Yki-Jarvinen H, Ryysy L, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajala S, Salo S, Seppala P, Tulokas T, Viikari J, Taskinen MR. Effect of obesity on the Response to Insulin Therapy in Noninsulin-Dependent Diabetes Mellitus. JCEM 1997; 82: 4037-43.
35. Franssila-Kallunki A, Groop L. Factors associated with basal metabolic rate in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 962-6.
36. Lindstrom T, Eriksson P, Olsson AG, Arnqvist HJ. Long-Term Improvement of Glycemic Control by Insulin Treatment in NIDDM Patients with Secondary Failure. Diabetes Care 1994; 17: 719-21.
37. Rigalleau V, Delafaye C, Baillet L, et al. Composition of insulin-induced body weight gain in diabetic patients: a body bio-impedance study. Diabetes Metab 1999; 25: 321-8.
38. DCCT Group. Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001; 24: 1711-21.
39. Welle S, Nair K-S, Lockwood D. Effect of a sulfonlyurea and insulin on energy expenditure in type 2 diabetes mellitus. J Clin Endocrinol Metab 1988; 66: 593-7.
40. Bogardus C, Taskinen MR, Zawadzki J, Lillioja S, Mott D, Howard BV. Increased resting metabolic rates in obese subjects with non-insulin-dependant diabetes mellitus and the effect of sulfonylurea therapy. Diabetes 1986; 35: 1-5.
41. Larger E, Rufat P, Dubois-Laforgue D, Ledoux S. Insulin therapy does not itself induce weight gain in patients with type 2 diabetes (Lett). Diabetes Care 2001; 24: 1849-50.
42. Looker HC, Knowler WC, Hanson RL. Changes in BMI and weight before and after the development of type 2 diabetes. Diabetes Care 2001; 24: 1917-22.
43. Bitz C, Toubro S, Larsen TM, Harder H, Rennie KL, Jebb SA, Astrup A. Increased 24-h Energy Expenditure in Type 2 Diabetes. Diabetes Care 2004; 27: 2416-21.
44. Fontvielle AM, Lillioja S, Ferraro RT, Ravussin E. Twenty-four hour energy expenditure in Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992; 354: 753-9.
45. Weyer C, Bogardus C, Pratley RE. Metabolic factors contributing to increased resting metabolic rate and decreased insulin-induced thermogenesis during the development of type 2 diabetes. Diabetes 1999; 48: 1607-14.
46. Gougeon R, Lamarche M, Yale JF, Venuta T. The prediction of resting energy expenditure in type 2 diabetes mellitus is improved by factoring for glycaemia. Int J Obes 2002; 26: 1547-52.
47. Martin K, Rust PF, Wallace P, Garvey WT. Estimation of resting energy expenditure considering effects of race and diabetes status. Diabetes Care 2004; 27: 1405-11.
48. Huang KC, Kormas N, Steinbeck K, Loughnan G, Caterson ID. Resting metabolic rate in severely obese diabetic and nondiabetic subjects. Obes Res 2004; 12: 840-5.
49. Stump CS, Short KR, Bigelow ML, Schimke JM, Nair KS. Effect of insulin on human skeletal muscle mitochondrial ATP production, protein synthesis, and mRNA transcripts. Proc Natl Acad Sci USA 2003; 100: 7996-7800.
50. Petersen KF, Befroy D, Dufour S, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003; 300: 1140-2.
51. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Eng J Med 2004; 350: 664-71.
52. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight N Eng J Med 1995; 332: 621-8.
53. Carlisle HJ, Dubuc PU. Temperature preference of genetically obese (ob/ ob) mice. Physiol Behav 1984; 33:899-902.
54. Dubuc PU. Interactions between insulin and glucocorticoids in the maintenance of genetic obesity. Am J Physiol 1992; 263:E550-5.
55. Spiegelman BM, Lowell B, Napolitano A, et al. Adrenal glucocorticoids regulate adipsin gene expression in genetically obese mice. J Biol Chem 1989; 264: 1811-5.
56. Chong PK, Jung RT, Rennie MJ, Scrimgeour CM. Energy expenditure in lean and obese diabetic patients using the doubly labelled water method. Diabet Med 1993; 10: 729-35.
57. Blundell JE, Tremblay A. Appetite control and energy (fuel) balance. Nutr Res Rev 1995; 8: 225-42.
58. Willing AE, Walls EK, Koopmans HS. Insulin increases the daily food intake of diabetic rats on high and low fat diets. Physiol Behav 1994; 56: 983-91.
59. Friedman MI, Ramirez I. Food intake in diabetic rats: relationship to metabolic effects of insulin treatment. Physiol Behav 1994; 56: 373-8.
60. Willing AE, Walls EK, Koopmans HS. Insulin infusion stimulates daily food intake and body weight gain in diabetic rats. Physiol Behav 1990; 48: 893-8.
61. Campfield LA, Smith FJ. Functional coupling between transient declines in blood glucose and feeding behavior: temporal relationship. Brain Res Bull 1986; 17: 427-33.
62. Campfield LA, Smith FJ, Rosenbaum M, Hirsch J. Human eating: evidence for a physiological basis using a modified paradigm. Neurosci Biobehav Rev 1996 20: 133-7
63. Campfield LA, Smith FJ. Transient declines in blood glucose signal meal initiation. Int J Obes 1990; 14: 15-31
64. Melanson KJ, Westerterp-Plantenga MS, Campfield LA, Saris WHM. Blood glucose and meal patterns in time-blinded males, after aspartame, carbohydrate, and fat consumption, in relation to sweetness perception. Br J Nutr 1999; 82: 437-46.
65. Spyer G, Hattersley AT, MacDonald IA, Arniel S, MacLeod KM. Hypoglycaemic counter-regulation at normal blood glucose concentrations in patients with well controlled type-2 diabetes. Lancet 2000; 356:1970-4.
66. Perros P, MacFarlane TW, Counsell C, Frier BM. Altered taste sensation in newly-diagnosed NIDDM. Diabetes Care 1996; 19: 768-70.
67. Strachan MWJ, Ewing FME, Frier BM, Harper A, Deary IJ. Food cravings during acute hypoglycaemia in adults with type 1 diabetes. Physiol Behav 2004; 80: 675-82.
68. Mayer J. Glucostatic mechanism of regulation of food intake. N Eng J Med 1953; 249: 13-14.
69. Campfield LA, Smith FJ. Blood glucose dynamics and control of meal initiation: a pattern detection and recognition theory. Physiol Rev 2003; 83: 25-58.
70. Song Z, Levin BE, Mc Ardle JJ, et al. Convergence of pre and postsynaptic influences on glucosensing neurons in ventromedial hypothalamic nucleus. Diabetes 2001; 50: 2673-81.
71. 18Fluoro-Deoxyglucose Positron Emission Tomography Study. Diabetes 2002; 51: 3384-90.
72. Brown AM. Brain glycogen re-awakened. J Neurochem 2004; 89: 537-52.
73. Gruetter R. Glycogen: the forgotten cerebral energy store. J Neurosci Res 2003; 15: 179-83.
74. Oz G, Henry PG, Seaquist ER, Gruetter R. Direct, noninvasive measurement of brain glycogen metabolism in humans. Neurochem Int 2003; 43: 323-9.
75. Morkan M, Mitrakou A, Veneman T, et al. Hypoglycemia unawareness in IDDM. Diabetes Care 1994; 17: 1397-1403
76. Muhlhauser I, Overmann H, Bender R, Bott U, Berger M. Risk factors of severe hypoglycemia in adult patients with Type 1 diabetes- a prospective population based study. Diabetologia 1998; 41: 1274-82.
77. Dewan S, Gillett A, Mugarza JA, Dovey TM, Halford JC, Wilding JP. Effects of insulin-induced hypoglycaemia on energy intake and food choice at a subsequent test meal. Diabetes Metab Res Rev 2004; 20: 405-410.
78. Rodin J, Wack J, Ferrannini E, DeFronzo RA. Effect of insulin and glucose on feeding behavior. Metabolism 1985; 34: 826-31.
79. Hopkins DF, Williams G. Insulin receptors are widely distributed in human brain and blind human and porcine insulin with equal affinity. Diabet Med 1997; 14: 1044-50.
80. Rayner DV, Thomas ME, Trayhurn P. Glucose transporters (GLUTs 1-4) and their mRNAs in regions of the rat brain: insulin-sensitive transporter expression in the cerebellum. Can J Physiol Pharmacol 1994; 72: 476-9.
81. Banks WA, Jaspan JB, Kastin AJ. Selective, Physiological Transport of Insulin Across the Blood-Brain Barrier: Novel Demonstration by Species-Specific Radioimmunassays. Peptides 1997; 18:1257-62.
82. Wallum BJ, Taborsky GJ Jr, Porte D Jr, Figlewicz DP, Jacobson L, Beard JC, Ward WK, Dorsa D. Cerebrospinal fluid insulin levels increase during intravenous insulin infusions in man. J Clin Endocrinol Metab 1987; 64:190-4.
83. Partridge WM, Eisenberg J, Yang J. Human blood brain barrier insulin receptor. J Neurochem 1985; 44: 1771-8.
84. Chavez M, Kaiyala K, Madden LJ, Schwartz MW, Woods SC. Intraventricular insulin and the level of maintained body weight in rats. Behav Neurosci 1995; 109: 528-31.
85. Brief DJ, Davis JD. Reduction of food intake and body weight by chronic intraventricular insulin infusion. Brain Res Bull 1984; 12: 571-5.
86. Florant GL, Singer L, Scheurink AJ, Park CR, Richardson RD, Woods SC. Intraventricular insulin reduces food intake and body weight of marmots during the summer feeding period. Physiol Behav 1991; 49: 335-8.
87. Mc Gowan Mk, Andrews KM, Grossman SP. Chronic intrahypothalamic infusion of insulin or insulin antibodies alter body weight and food intake in the rat. Physiol Behav 1992; 51: 753-66.
88. Obici S, Feng Z, Karkanias G, Baskin DG, Rossetti L. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat Neurosci 2002; 5: 566-72.
89. Schwartz MW, Figlewicz DP, Baskin DG, Woods SC. Insulin and the central regulation of energy balance: Update 1994. Endocrine Rev 1994; 2: 109-13.
90. Sipols AJ, Baskin DG, Schwartz MW. Effect of intracerebroventricular insulin infusion on diabetic hyperphagia and hypothalamic neuropeptide gene expression. Diabetes 1995; 44: 147-51.
91. Ikeda H, West DB, Pustek JJ, Figlewicz DP, Greenwood MRC, Porte D Jr. Intraventricular insulin reduces food intake and body weight of lean but not obese Zucker rats. Appetite 1986; 7: 381-6.
92. Stockhorst U, de Fries D, Schottenfeld-Naor Y, Huebinger A, Steingrueber HJ, Scherbaum WA. Intranasally administered insulin and its CNS effects in healthy humans: unconditioned and conditioned responses (unpublished data).
93. Kern W, Born J, Schreiber H, Fehm HL. Central nervous system effects of intranasally administered insulin during euglycemia in men. Diabetes 1999; 48: 557-63.
94. Banks WA, Farrell CL. Impaired transport of leptin across the blood-brain barrier in obesity is acquired and reversible. Am J Physiol Metab 2003; 285:E10-5.
95. Gerozissis K. Brain insulin and feeding: a bi-directional communication. Eur J Pharmacol 2004; 19: 59-70.
96. Baura GD, Foster DM, Kaiyala K, Porte Jr D, Kahn SE, Schwartz MW. Insulin transport from plasma into the central nervous system is inhibited by dexamethasone in dogs. Diabetes 1996; 45: 86-90.
97. Banks WA. The source of cerebral insulin. Eur J Pharmacol 2004; 490: 5-12.